Kos Mitja, Obradovic Marko, Mrhar Ales
Faculty of Pharmacy, University of Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia.
Eur J Cancer. 2008 Feb;44(3):408-18. doi: 10.1016/j.ejca.2007.11.020. Epub 2007 Dec 26.
The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries.
Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated.
The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries.
The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.
本研究旨在比较斯洛文尼亚与部分欧洲国家在获取靶向肿瘤药物方面的情况。
通过使用靶向肿瘤药物的销售数据来评估其可及性，该数据以每例因该药物所针对癌症死亡的个体的毫克数来表示。
在大多数情况下，斯洛文尼亚引入靶向肿瘤药物的时间与对比国家相似，但阿仑单抗和利妥昔单抗除外。在大多数情况下，斯洛文尼亚靶向肿瘤药物的使用量低于其他对比国家。直到2005年，伊布替尼单抗在斯洛文尼亚都未被使用，法国、瑞士和英国的情况与之类似。2003年后，斯洛文尼亚曲妥珠单抗的使用量开始大幅上升，接近对比国家的平均使用水平。
在大多数情况下，斯洛文尼亚靶向肿瘤药物的使用量低于对比国家。
